This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
by Zacks Equity Research
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.
INCYNegative Net Change NVSNegative Net Change MIRMNegative Net Change
biotechnology biotechs medical pharmaceuticals
HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase
by Ekta Bagri
Harmony Biosciences is broadening beyond Wakix with pitolisant programs, orexin research and rare epilepsy assets to diversify growth.
HRMYPositive Net Change ALKSNegative Net Change JAZZPositive Net Change
biotechnology biotechs
Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline
by Ekta Bagri
Harmony Biosciences is leveraging Wakix growth to expand its neuroscience pipeline, while advancing pitolisant programs and rare disease assets.
HRMYPositive Net Change JAZZPositive Net Change AXSMPositive Net Change
biotechs pharmaceuticals
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
by Zacks Equity Research
Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.
MRNAPositive Net Change MRKNegative Net Change IMCRPositive Net Change INDVNegative Net Change
biotechs medical messenger-rna pharmaceuticals
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
by Kinjel Shah
SYRE has surged on pipeline progress and a strong cash position, but with no product revenue and key trial data still ahead, is the risk already priced in?
SYRENegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs
SYRE and Spyre Ride New IBD Trends in Biotech Drug Design
by Kinjel Shah
SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.
SYRENegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
by Kinjel Shah
The investment case for Spyre Therapeutics is built around a straightforward but high-risk question: can its broad IBD pipeline produce meaningful clinical proof-of-concept data?
JNJNegative Net Change ABBVNegative Net Change SYRENegative Net Change
biotechs
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
by Zacks Equity Research
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
ACADPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?
by Ahan Chakraborty
NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.
NVONegative Net Change VKTXNegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
by Zacks Equity Research
AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod following a positive CHMP opinion.
AZNNegative Net Change AMRNPositive Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechs